Ayala Pharmaceuticals (NASDAQ:ADXS) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report issued on Wednesday morning. The firm issued a sell rating on the stock.

Ayala Pharmaceuticals Stock Down 74.3 %

ADXS opened at $0.03 on Wednesday. Ayala Pharmaceuticals has a twelve month low of $0.00 and a twelve month high of $1.49. The company has a fifty day moving average of $0.03 and a 200-day moving average of $0.25. The stock has a market cap of $1.15 million, a PE ratio of 0.00 and a beta of 1.72.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.